Carl Zeiss Meditec ‘CZM’ released its Q4 17 results which were above our estimates as well as market consensus. Revenue at CER surged 15.3% (c.4% above the street’s estimates) led by higher than expected sales in the lynchpin Ophthalmic Devices segment (+19.7%; accounts for c.74% of Q4 17 sales). Within the segment, momentum was driven by the refractive lasers and intraocular lenses/IOL businesses while the diagnostic division also performed well despite stiff competition. T
27 Dec 2017
Strong finish to the year; mid-term guidance upgrade in line with expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to the year; mid-term guidance upgrade in line with expectations
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
27 Dec 2017 -
Author:
Sumit Sayal -
Pages:
3
Carl Zeiss Meditec ‘CZM’ released its Q4 17 results which were above our estimates as well as market consensus. Revenue at CER surged 15.3% (c.4% above the street’s estimates) led by higher than expected sales in the lynchpin Ophthalmic Devices segment (+19.7%; accounts for c.74% of Q4 17 sales). Within the segment, momentum was driven by the refractive lasers and intraocular lenses/IOL businesses while the diagnostic division also performed well despite stiff competition. T